This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
midgardfinance.com
midgardfinance.com
did:plc:6elkozr74dmgtebnjmwcre7e
SURMOUNT-5: Tirzepatide −20.2% vs Semaglutide −13.7%.
TRIUMPH-1 (retatrutide) just reported: -28.3%. Read this before the cross-trial comparison.
🇺🇸 $LLY 🇩🇰 $NVO $NOVO
https://www.midgardfinance.com/blog/2026/05/15/glp1-trial-inclusion-criteria-drift/
#GLP1 #Obesity #Retatrutide
2026-05-21T20:57:52.163Z